AstraZeneca Reports Positive Phase 3 Data for Eneboparatide in Chronic Hypoparathyroidism

Why It Matters

The data demonstrate a potential disease‑modifying therapy that could reduce the pill burden and long‑term renal risks associated with conventional hypoparathyroidism treatment, positioning AstraZeneca as a leader in a niche rare‑disease market.

Key Takeaways

• 31.1% achieved calcium normalization and supplement independence at 24 weeks
• Placebo group only 5.9% reached same composite endpoint
• Trial enrolled 202 adults, randomized 2:1 to eneboparatide
• Immunogenicity observed in most patients, reducing efficacy in some
• Eneboparatide adds to AstraZeneca’s rare‑disease peptide portfolio

Pulse Analysis

Chronic hypoparathyroidism remains a therapeutic challenge, with patients relying on high‑dose oral calcium and active vitamin D to maintain serum calcium. This regimen often leads to fluctuating calcium levels, a substantial pill burden, and heightened risk of nephrocalcinosis and kidney stones. Emerging PTH replacement strategies aim to restore physiologic calcium regulation, offering a more balanced approach that could mitigate these complications.

The CALYPSO Phase 3 trial provides the most robust evidence to date for eneboparatide, a selective PTH1‑receptor agonist. In a 24‑week double‑blind study of 202 adults, 31.1% of eneboparatide‑treated participants achieved the dual goal of normal serum calcium and independence from active vitamin D and high‑dose calcium, versus just 5.9% on placebo. Although the drug showed statistically significant improvements, the emergence of anti‑drug antibodies in the majority of patients raises concerns about durability of response, a factor that will be closely watched as the trial extends to 52 weeks.

For AstraZeneca, the positive read‑out expands its rare‑disease pipeline, built after the 2024 acquisition of Amolyt Pharma. Success could unlock a high‑margin niche market and reinforce the company’s strategic shift toward peptide therapeutics targeting endocrine pathways. Analysts will gauge the long‑term safety profile and immunogenicity mitigation strategies before projecting commercial potential, but the CALYPSO results already signal a meaningful shift in how chronic hypoparathyroidism may be managed in the coming years.